nivolumab
Summary
Nivolumab is a human IgG4 monoclonal antibody that inhibits PD-1 (programmed cell death protein 1), an immune checkpoint receptor on activated T cells. By blocking PD-1's interaction with PD-L1/PD-L2 on tumor cells, it restores T-cell mediated anti-tumor immunity. It is FDA-approved for multiple malignancies including melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, and others.
Detail
Nivolumab belongs to the class of immune checkpoint inhibitors used in cancer immunotherapy. Mechanism: Tumor cells often upregulate PD-L1 to engage PD-1 on cytotoxic T lymphocytes, delivering an inhibitory signal that suppresses T-cell activation and allows immune evasion. Nivolumab binds PD-1, preventing this interaction, thereby 'releasing the brakes' on T cells and enhancing their ability to recognize and destroy tumor cells. Clinical uses: Approved for metastatic melanoma, NSCLC, renal cell carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, hepatocellular carcinoma, colorectal cancer (MSI-high), and others; often used alone or combined with ipilimumab (anti-CTLA-4) for synergistic effect. Adverse effects: Because it removes immune checkpoints, it can cause immune-related adverse events (irAEs) due to loss of self-tolerance, including pneumonitis, colitis, hepatitis, endocrinopathies (thyroiditis, hypophysitis, adrenal insufficiency, type 1 diabetes), dermatitis, and rarely myocarditis. Management of irAEs typically involves corticosteroids and holding/discontinuing the drug depending on severity. Key boards points: Differentiate from CTLA-4 inhibitors (ipilimumab) and PD-L1 inhibitors (atezolizumab, durvalumab, avelumab); understand checkpoint biology as tested concept; recognize irAEs as classic complication distinguishing immunotherapy from traditional chemotherapy toxicity (e.g., no significant myelosuppression, alopecia, or GI mucositis typically).
Sources
- Katzung's Basic & Clinical Pharmacology
- UpToDate: Nivolumab drug monograph
- First Aid for the USMLE Step 1
- NCCN Guidelines for Immunotherapy
- Robbins Basic Pathology - Immune Checkpoint Inhibitors section
Reviewed by AnkiBoss editorial — medical student review. Information here is for study reference only and is not medical advice. Spotted an error? Let us know.